Bree F, Nguyen P, Urien S, Riant P, Albengres E, Fenner H, Tillement J P
Laboratoire Hospitalo-Universitaire de Pharmacologie de Paris, France.
Fundam Clin Pharmacol. 1989;3(3):267-79. doi: 10.1111/j.1472-8206.1989.tb00456.x.
Blood binding of tenoxicam was studied in vitro by equilibrium dialysis. Isolated human plasma proteins and blood cells were checked, and the distribution of the bound form was then calculated. The results showed that tenoxicam is mainly bound to HSA and that binding percentages are not different when measured in plasma (98.4%) and in an HSA solution at physiological concentration (704 microM, 98.15%). In these conditions, within the range of 1-150 microM, the tenoxicam binding percentage remained constant, evidence of a nonsaturable process. When a lower HSA concentration (10 microM) was used, the binding parameters of the tenoxicam interaction were calculated by using the same equilibrium dialysis data, by 3 methods of analysis- a stoichiometric method and site-oriented methods, fixing or not the number of HSA binding sites (n) as integer values. The best fit was observed with the first method, suggesting that two main interactions occurred. The site-oriented method gave lesser fits, the better being observed when n was not fixed. Its value, 1.77, suggest the possibility of two binding sites, one of them not preformed. The effects of known markers of site I, warfarin and apazone, of site II, diazepam and ibuprofen and of palmitic acid showed that tenoxicam is bound simultaneously to both sites I and II. The binding capacity of site I for tenoxicam is enhanced by diazepam: as this compound alone is bound to site II, this result suggests that the two HSA binding sites are not independent.
通过平衡透析法在体外研究了替诺昔康的血液结合情况。对分离出的人血浆蛋白和血细胞进行了检测,然后计算结合形式的分布。结果表明,替诺昔康主要与人血清白蛋白(HSA)结合,在血浆(98.4%)和生理浓度的HSA溶液(704微摩尔,98.15%)中测得的结合百分比没有差异。在这些条件下,在1 - 150微摩尔范围内,替诺昔康的结合百分比保持恒定,这是一个非饱和过程的证据。当使用较低的HSA浓度(10微摩尔)时,利用相同的平衡透析数据,通过三种分析方法——化学计量法和面向位点的方法,将HSA结合位点数量(n)固定或不固定为整数值,计算替诺昔康相互作用的结合参数。第一种方法观察到最佳拟合,表明发生了两种主要相互作用。面向位点的方法拟合度较低,当n不固定时观察到较好的拟合。其值为1.77,表明可能存在两个结合位点,其中一个不是预先形成的。位点I的已知标记物华法林和阿扎丙宗、位点II的地西泮和布洛芬以及棕榈酸的作用表明,替诺昔康同时与位点I和位点II结合。地西泮增强了位点I对替诺昔康的结合能力:由于该化合物单独与位点II结合,这一结果表明两个HSA结合位点不是独立的。